Many faces of graft-versus-host disease.
Allogeneic haematopoietic stem cell transplantation is increasingly used in the treatment of malignant and non-malignant disorders. Despite ongoing advances in the field, morbidity and mortality related to graft-versus-host disease remains a major barrier to its application. Graft-versus-host disease is a difficult-to-diagnose disease. Dermatologists are involved due to its diverse cutaneous expression. In order to appropriately diagnose, classify and treat this complex disease, knowledge of its expanding cutaneous expression is required. This review provides a synopsis of the clinical manifestations of acute, lichenoid and sclerodermatous phases of graft-versus-host disease with a look at the current evidence surrounding its differential diagnosis.
Peñas
Pablo F
PF
Department of Dermatology, Westmead Hospital, University of Sydney, Sydney, Hawkesbury Road, Westmead, NSW 2145, Australia. pfernandezpenas@med.usyd.edu.au
Zaman
Sarah
S
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006680:HLA Antigens / Q000032:analysis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D012871:Skin Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D006680:HLA Antigens; D007166:Immunosuppressive Agents